A pharmacokinetic profile of desloratadine in healthy adults, including elderly

Clinical Pharmacokinetics

Volumn 41, Issue SUPPL. 1, 2002, Pages 13-19

  Affrime, M ^a   Gupta, S ^a   Banfield, C ^a   Cohen, A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Peninsular Testing Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYDESLORATADINE; DESLORATADINE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MULTICENTER STUDY; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0036074366     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241001-00003     Document Type: Article

References (10)

1. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology
2. Cardiovascular safety of second-generation antihistamines
3. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving
4. Sedation with 'non-sedating' antihistamines: Four prescription-event monitoring studies in general practice
5. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons
6. Lack of electrocardiographic effects of multiple high doses of desloratadine
7. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine
8. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole
9. Lack of clinically relevant interaction between desloratadine and erythromycin